Acquired by Amgen in Oct 2023
HZNP - Horizon Therapeutics Public Limited Company
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Dublin,
Ireland
Type: Equity
HZNP price evolution
HZNP
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2469.41 | $2316.4 | $2357.59 | $2135.27 |
| Short term investments | ||||
| Net receivables | $717.42 | $624.7 | $676.35 | $646.39 |
| Inventory | $170.32 | $164.5 | $169.56 | $190.26 |
| Total current assets | $3921.96 | $3602.85 | $3652.84 | $3412.01 |
| Long term investments | ||||
| Property, plant & equipment | $362.33 | $355.87 | $440.01 | $317.69 |
| Goodwill & intangible assets | $3497.1 | $3586.7 | $3675.32 | $3768.23 |
| Total noncurrent assets | $5376.78 | $5390.6 | $5461.77 | $5615.85 |
| Total investments | ||||
| Total assets | $9298.74 | $8993.45 | $9114.62 | $9027.86 |
| Current liabilities | ||||
| Accounts payable | $85.54 | $76.62 | $155.8 | $32.11 |
| Deferred revenue | ||||
| Short long term debt | $16 | $16 | $16 | $16 |
| Total current liabilities | $917.68 | $884.89 | $949.14 | $860.61 |
| Long term debt | $2541.46 | $2544.23 | $2546.84 | $2549.14 |
| Total noncurrent liabilities | $3070.1 | $3013 | $3093.3 | $3133.56 |
| Total debt | $2557.46 | $2560.23 | $2562.84 | $2565.14 |
| Total liabilities | $3987.78 | $3897.89 | $4042.44 | $3994.18 |
| Shareholders' equity | ||||
| Retained earnings | $771.76 | $644.69 | $590.01 | $606.28 |
| Other shareholder equity | $21.61 | $6.68 | $12.53 | $7.46 |
| Total shareholder equity | $5310.96 | $5095.56 | $5072.17 | $5033.69 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2357.59 | $1584.16 | $2083.48 | $1080.04 |
| Short term investments | ||||
| Net receivables | $676.35 | $632.77 | $659.7 | $408.69 |
| Inventory | $169.56 | $225.73 | $75.28 | $53.8 |
| Total current assets | $3652.84 | $2799.77 | $3070.41 | $1686.1 |
| Long term investments | $10.6 | |||
| Property, plant & equipment | $440.01 | $292.3 | $189.04 | $30.16 |
| Goodwill & intangible assets | $3675.32 | $4026.83 | $2196.63 | $2116.3 |
| Total noncurrent assets | $5461.77 | $5877.96 | $3002.21 | $2749.93 |
| Total investments | ||||
| Total assets | $9114.62 | $8677.73 | $6072.62 | $4436.03 |
| Current liabilities | ||||
| Accounts payable | $155.8 | $30.13 | $37.71 | $21.51 |
| Deferred revenue | ||||
| Short long term debt | $16 | $16 | ||
| Total current liabilities | $949.14 | $886.57 | $875.74 | $723.17 |
| Long term debt | $2546.84 | $2555.23 | $1003.38 | $1352.84 |
| Total noncurrent liabilities | $3093.3 | $3118.76 | $1171.53 | $1527.42 |
| Total debt | $2562.84 | $2571.23 | $1003.38 | $1352.84 |
| Total liabilities | $4042.44 | $4005.34 | $2047.27 | $2250.59 |
| Shareholders' equity | ||||
| Retained earnings | $590.01 | $318.61 | -$215.89 | -$605.68 |
| Other shareholder equity | $12.53 | -$14.99 | -$0.14 | -$1.91 |
| Total shareholder equity | $5072.17 | $4672.39 | $4025.35 | $2185.45 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $944.96 | $832.06 | $942.03 | $925.36 |
| Cost of revenue | $219.96 | $208.56 | $240.79 | $234.13 |
| Gross Profit | $725 | $623.5 | $701.24 | $691.23 |
| Operating activities | ||||
| Research & development | $150.03 | $134.15 | $117.53 | $114.06 |
| Selling, general & administrative | $434.13 | $453.35 | $372.53 | $397.56 |
| Total operating expenses | $579.98 | $588.85 | $527.47 | $532.9 |
| Operating income | $145.02 | $34.65 | $173.77 | $158.33 |
| Income from continuing operations | ||||
| EBIT | $147.35 | $34.74 | $172.89 | $157.56 |
| Income tax expense | $8.18 | -$35.48 | $33.92 | -$0.76 |
| Interest expense | $12.1 | $15.54 | $18.56 | $22.48 |
| Net income | ||||
| Net income | $127.07 | $54.68 | $120.41 | $135.84 |
| Income (for common shares) | $127.07 | $54.68 | $120.41 | $135.84 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3629.04 | $3226.41 | $2200.43 | $1300.03 |
| Cost of revenue | $920.2 | $794.51 | $532.7 | $362.18 |
| Gross Profit | $2708.85 | $2431.9 | $1667.73 | $937.85 |
| Operating activities | ||||
| Research & development | $437.96 | $431.99 | $209.36 | $103.17 |
| Selling, general & administrative | $1541.05 | $1446.41 | $973.23 | $697.11 |
| Total operating expenses | $2097 | $1886.98 | $1174.32 | $812.19 |
| Operating income | $611.85 | $544.92 | $493.41 | $125.67 |
| Income from continuing operations | ||||
| EBIT | $610.64 | $543.89 | $461.26 | $66.86 |
| Income tax expense | $5.45 | -$71.66 | $11.85 | -$593.24 |
| Interest expense | $83.71 | $81.06 | $59.62 | $87.09 |
| Net income | ||||
| Net income | $521.48 | $534.49 | $389.8 | $573.02 |
| Income (for common shares) | $521.48 | $534.49 | $389.8 | $573.02 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | $127.07 | $54.68 | $120.41 | $135.84 |
| Operating activities | ||||
| Depreciation | $96.28 | $94.86 | $98.77 | $99.08 |
| Business acquisitions & disposals | -$15 | -$22.25 | -$40 | |
| Stock-based compensation | $60.27 | $58.12 | $44.59 | $45.07 |
| Total cash flows from operations | $161.47 | $86.32 | $426.39 | $366.46 |
| Investing activities | ||||
| Capital expenditures | -$18.47 | -$24.13 | -$24.86 | -$14.82 |
| Investments | -$1.56 | -$2.62 | -$1.96 | -$2.21 |
| Total cash flows from investing | -$20.03 | -$41.75 | -$49.07 | -$32.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.54 | $3.42 | -$143.67 | -$86.95 |
| Net borrowings | -$4 | -$4 | -$4 | -$4 |
| Total cash flows from financing | $9.03 | -$88.13 | -$160.97 | -$94.37 |
| Effect of exchange rate | $2.54 | $2.37 | $5.96 | -$2.1 |
| Change in cash and equivalents | $153.01 | -$41.19 | $222.32 | $237.97 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | $521.48 | $534.49 | $389.8 | $573.02 |
| Operating activities | ||||
| Depreciation | $390.39 | $353.75 | $279.45 | $237.16 |
| Business acquisitions & disposals | -$65.37 | -$2845.28 | -$262.31 | |
| Stock-based compensation | $182.1 | $219.09 | $146.63 | $91.22 |
| Total cash flows from operations | $1257.84 | $1035.27 | $555.69 | $426.33 |
| Investing activities | ||||
| Capital expenditures | -$64.03 | -$74.6 | -$158.45 | -$17.86 |
| Investments | -$4.6 | -$24.67 | -$13.31 | |
| Total cash flows from investing | -$134 | -$2994.11 | -$464.07 | -$17.86 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$194.71 | $73.09 | $972.82 | $362.99 |
| Net borrowings | -$16 | $1562.99 | -$1.74 | -$625.17 |
| Total cash flows from financing | -$347.96 | $1470.12 | $904.58 | -$290.45 |
| Effect of exchange rate | -$2.45 | -$10.61 | $7.24 | -$0.11 |
| Change in cash and equivalents | $773.43 | -$499.32 | $1003.44 | $117.92 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 228.94M |
| Revenue | $3.64B |
|---|---|
| EBITDA | $901.54M |
| EBIT | $512.54M |
| Net Income | $438.00M |
| Revenue Q/Q | 7.82% |
| Revenue Y/Y | -4.42% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 23.10 |
| Cash/Share | 10.79 |
| EPS | $1.91 |
|---|---|
| ROA | 4.81% |
| ROE | 8.54% |
| Debt/Equity | 0.80 |
|---|---|
| Net debt/EBITDA | 1.68 |
| Current ratio | 4.27 |
| Quick ratio | 4.09 |